SEARCH

SEARCH BY CITATION

References

  • Abe K., Chisaka O., Van Roy F. and Takeichi M. (2004) Stability of dendritic spines and synaptic contacts is controlled by alpha N-catenin. Nat. Neurosci. 7, 357363.
  • Abou-Sleymane G., Chalmel F., Helmlinger D. et al. (2006) Polyglutamine expansion causes neurodegeneration by altering the neuronal differentiation program. Hum. Mol. Genet. 15, 691703.
  • Allen P. B., Greenfield A. T., Svenningsson P., Haspeslagh D. C. and Greengard P. (2004) Phactrs 1–4: a family of protein phosphatase 1 and actin regulatory proteins. Proc. Natl. Acad. Sci. USA 101, 71877192.
  • Bellenchi G. C., Gurniak C. B., Perlas E., Middei S., Ammassari-Teule M. and Witke W. (2007) N-Cofilin is associated with neuronal migration disorders and cell cycle control in the cerebral cortex. Genes Dev. 21, 23472357.
  • Camargo L. M., Collura V., Rain J. C., Mizuguchi K., Hermjakob H., Kerrien S., Bonnert T. P., Whiting P. J. and Brandon N. J. (2007) Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol. Psychiatry 12, 7486.
  • Carlin R. K., Grab D. J., Cohen R. S. and Siekevitz P. (1980) Isolation and characterization of postsynaptic densities from various brain regions: enrichment of different types of postsynaptic densities. J. Cell Biol. 86, 831845.
  • Cartmell J., Monn J. A. and Schoepp D. D. (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J. Pharmacol. Exp. Ther. 291, 161170.
  • Cartmell J., Monn J. A. and Schoepp D. D. (2000) The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. Eur. J. Pharmacol. 400, 221224.
  • Chen G., Rajkowska G., Du F., Seraji-Bozorgzad N. and Manji H. K. (2000) Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 75, 17291734.
  • Collins M. O., Husi H., Yu L., Brandon J. M., Anderson C. N., Blackstock W. P., Choudhary J. S. and Grant S. G. (2006) Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. J. Neurochem. 97(Suppl. 1), 1623.
  • Cooper J. A. and Schafer D. A. (2000) Control of actin assembly and disassembly at filament ends. Curr. Opin. Cell Biol. 12, 97103.
  • Coyle J. T. and Duman R. S. (2003) Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38, 157160.
  • Cumming R. C., Dargusch R., Fischer W. H. and Schubert D. (2007) Increase in expression levels and resistance to sulfhydryl oxidation of peroxiredoxin isoforms in amyloid beta-resistant nerve cells. J. Biol. Chem. 282, 3052330534.
  • Dateki M., Horii T., Kasuya Y. et al. (2005) Neurochondrin negatively regulates CaMKII phosphorylation, and nervous system-specific gene disruption results in epileptic seizure. J. Biol. Chem. 280, 2050320508.
  • Dosemeci A., Reese T. S., Petersen J. and Tao-Cheng J. H. (2000) A novel particulate form of Ca(2+)/calmodulin-dependent [correction of Ca(2+)/CaMKII-dependent] protein kinase II in neurons. J. Neurosci. 20, 30763084.
  • Dosemeci A., Makusky A. J., Jankowska-Stephens E., Yang X., Slotta D. J. and Markey S. P. (2007) Composition of the synaptic PSD-95 complex. Mol. Cell Proteomics 6, 17491760.
  • Emes R. D., Pocklington A. J., Anderson C. N. et al. (2008) Evolutionary expansion and anatomical specialization of synapse proteome complexity. Nat. Neurosci. 11, 799806.
  • Esposito K., Reierson G. W., Luo H. R., Wu G. S., Licinio J. and Wong M. L. (2009) Phosphodiesterase genes and antidepressant treatment response: a review. Ann. Med. 41, 177185.
  • Fallin M. D., Lasseter V. K., Avramopoulos D. et al. (2005) Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am. J. Hum. Genet. 77, 918936.
  • Fatemi S. H., Earle J. A., Stary J. M., Lee S. and Sedgewick J. (2001) Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia. Neuroreport 12, 32573262.
  • Frazier J. A., Chiu S., Breeze J. L. et al. (2005) Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder. Am. J. Psychiatry 162, 12561265.
  • Fung H. C., Scholz S., Matarin M. et al. (2006) Genome-wide genotyping in Parkinson’s disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 5, 911916.
  • Gamm D. M., Melvan J. N., Shearer R. L., Pinilla I., Sabat G., Svendsen C. N. and Wright L. S. (2008) A novel serum-free method for culturing human prenatal retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 49, 788799.
  • Gottlicher M., Minucci S., Zhu P. et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 69696978.
  • Grover D., Verma R., Goes F. S., Mahon P. L., Gershon E. S., McMahon F. J. and Potash J. B. (2009) Family-based association of YWHAH in psychotic bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B, 977983.
  • Hakak Y., Walker J. R., Li C., Wong W. H., Davis K. L., Buxbaum J. D., Haroutunian V. and Fienberg A. A. (2001) Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. USA 98, 47464751.
  • Hemby S. E., Ginsberg S. D., Brunk B., Arnold S. E., Trojanowski J. Q. and Eberwine J. H. (2002) Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. Arch. Gen. Psychiatry 59, 631640.
  • Hibino H., Pironkova R., Onwumere O., Vologodskaia M., Hudspeth A. J. and Lesage F. (2002) RIM binding proteins (RBPs) couple Rab3-interacting molecules (RIMs) to voltage-gated Ca(2+) channels. Neuron 34, 411423.
  • Hodges A., Strand A. D., Aragaki A. K. et al. (2006) Regional and cellular gene expression changes in human Huntington’s disease brain. Hum. Mol. Genet. 15, 965977.
  • Hoy J. L., Constable J. R., Vicini S., Fu Z. and Washbourne P. (2009) SynCAM1 recruits NMDA receptors via protein 4.1B. Mol. Cell. Neurosci. 42, 466483.
  • Hunsberger J., Austin D. R., Henter I. D. and Chen G. (2009) The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin. Neurosci. 11, 333348.
  • Hurko O. and Ryan J. L. (2005) Translational research in central nervous system drug discovery. NeuroRx 2, 671682.
  • Ikeda M., Hikita T., Taya S. et al. (2008) Identification of YWHAE, a gene encoding 14-3-3epsilon, as a possible susceptibility gene for schizophrenia. Hum. Mol. Genet. 17, 32123222.
  • Johnston-Wilson N. L., Sims C. D., Hofmann J. P., Anderson L., Shore A. D., Torrey E. F. and Yolken R. H. (2000) Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol. Psychiatry 5, 142149.
  • Junqueira M., Spirin V., Balbuena T. S., Thomas H., Adzhubei I., Sunyaev S. and Shevchenko A. (2008) Protein identification pipeline for the homology-driven proteomics. J. Proteomics 71, 346356.
  • Kato T. (2007) Molecular genetics of bipolar disorder and depression. Psychiatry Clin. Neurosci. 61, 319.
  • Kawano Y., Yoshimura T., Tsuboi D., Kawabata S., Kaneko-Kawano T., Shirataki H., Takenawa T. and Kaibuchi K. (2005) CRMP-2 is involved in kinesin-1-dependent transport of the Sra-1/WAVE1 complex and axon formation. Mol. Cell. Biol. 25, 99209935.
  • Kim I. H., Park S. K., Hong S. T. et al. (2009) Inositol 1,4,5-trisphosphate 3-kinase a functions as a scaffold for synaptic Rac signaling. J. Neurosci. 29, 1403914049.
  • Knable M. B., Barci B. M., Webster M. J., Meador-Woodruff J. and Torrey E. F. (2004) Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. Mol. Psychiatry 9, 609620.
  • Kolesnikova T. V., Kazarov A. R., Lemieux M. E., Lafleur M. A., Kesari S., Kung A. L. and Hemler M. E. (2009) Glioblastoma inhibition by cell surface immunoglobulin protein EWI-2, in vitro and in vivo. Neoplasia 11, 7786.
  • Li H., Wetten S., Li L. et al. (2008) Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch. Neurol. 65, 4553.
  • Liska A. J. and Shevchenko A. (2003) Expanding the organismal scope of proteomics: cross-species protein identification by mass spectrometry and its implications. Proteomics 3, 1928.
  • Luscher C. and Huber K. M. (2010) Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. Neuron 65, 445459.
  • Luthi-Carter R., Strand A., Peters N. L. et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington’s disease. Hum. Mol. Genet. 9, 12591271.
  • MacDonald M. L., Naydenov A., Chu M., Matzilevich D. and Konradi C. (2006) Decrease in creatine kinase messenger RNA expression in the hippocampus and dorsolateral prefrontal cortex in bipolar disorder. Bipolar Disord. 8, 255264.
  • Maraganore D. M., de Andrade M., Lesnick T. G. et al. (2005) High-resolution whole-genome association study of Parkinson disease. Am. J. Hum. Genet. 77, 685693.
  • Martins-de-Souza D., Gattaz W. F., Schmitt A., Rewerts C., Marangoni S., Novello J. C., Maccarrone G., Turck C. W. and Dias-Neto E. (2009) Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J. Neural Transm. 116, 275289.
  • McFarland M. A., Ellis C. E., Markey S. P. and Nussbaum R. L. (2008) Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. Mol. Cell Proteomics 7, 21232137.
  • Middleton F. A., Peng L., Lewis D. A., Levitt P. and Mirnics K. (2005) Altered expression of 14-3-3 genes in the prefrontal cortex of subjects with schizophrenia. Neuropsychopharmacology 30, 974983.
  • Mori T., Wada T., Suzuki T., Kubota Y. and Inagaki N. (2007) Singar1, a novel RUN domain-containing protein, suppresses formation of surplus axons for neuronal polarity. J. Biol. Chem. 282, 1988419893.
  • Murdoch J. N., Doudney K., Gerrelli D., Wortham N., Paternotte C., Stanier P. and Copp A. J. (2003) Genomic organization and embryonic expression of Igsf8, an immunoglobulin superfamily member implicated in development of the nervous system and organ epithelia. Mol. Cell. Neurosci. 22, 6274.
  • Osterweil E., Wells D. G. and Mooseker M. S. (2005) A role for myosin VI in postsynaptic structure and glutamate receptor endocytosis. J. Cell Biol. 168, 329338.
  • Owuor K., Harel N. Y., Englot D. J., Hisama F., Blumenfeld H. and Strittmatter S. M. (2009) LGI1-associated epilepsy through altered ADAM23-dependent neuronal morphology. Mol. Cell. Neurosci. 42, 448457.
  • Parra M., Gascard P., Walensky L. D. et al. (2000) Molecular and functional characterization of protein 4.1B, a novel member of the protein 4.1 family with high level, focal expression in brain. J. Biol. Chem. 275, 32473255.
  • Perkins D. N., Pappin D. J., Creasy D. M. and Cottrell J. S. (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 35513567.
  • Phiel C. J., Zhang F., Huang E. Y., Guenther M. G., Lazar M. A. and Klein P. S. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 3673436741.
  • Pilo Boyl P., Di Nardo A., Mulle C. et al. (2007) Profilin2 contributes to synaptic vesicle exocytosis, neuronal excitability, and novelty-seeking behavior. EMBO J. 26, 29913002.
  • Pongrac J. L., Middleton F. A., Peng L., Lewis D. A., Levitt P. and Mirnics K. (2004) Heat shock protein 12A shows reduced expression in the prefrontal cortex of subjects with schizophrenia. Biol. Psychiatry 56, 943950.
  • Poulopoulos A., Aramuni G., Meyer G. et al. (2009) Neuroligin 2 drives postsynaptic assembly at perisomatic inhibitory synapses through gephyrin and collybistin. Neuron 63, 628642.
  • Rouach N., Byrd K., Petralia R. S. et al. (2005) TARP gamma-8 controls hippocampal AMPA receptor number, distribution and synaptic plasticity. Nat. Neurosci. 8, 15251533.
  • Sato J., Shimazu D., Yamamoto N. and Nishikawa T. (2008) An association analysis of synapse-associated protein 97 (SAP97) gene in schizophrenia. J. Neural. Transm. 115, 13551365.
  • Schulze T. G., Detera-Wadleigh S. D., Akula N. et al. (2009) Two variants in Ankyrin 3 (ANK3) are independent genetic risk factors for bipolar disorder. Mol. Psychiatry 14, 487491.
  • Schymick J. C., Scholz S. W., Fung H. C. et al. (2007) Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 6, 322328.
  • Sepulveda F. J., Bustos F. J., Inostroza E., Zuniga F. A., Neve R. L., Montecino M. A. and van Zundert B. (2010) Differential roles of NMDA receptor subtypes NR2A and NR2B in dendritic branch development and requirement of RasGRF1. J. Neurophysiol. 103, 17581770.
  • Sheng M. and Hoogenraad C. C. (2007) The postsynaptic architecture of excitatory synapses: a more quantitative view. Annu. Rev. Biochem. 76, 823847.
  • Shi Y., Vaden D. L., Ju S., Ding D., Geiger J. H. and Greenberg M. L. (2005) Genetic perturbation of glycolysis results in inhibition of de novo inositol biosynthesis. J. Biol. Chem. 280, 4180541810.
  • Slotta D. J., McFarland M. A. and Markey S. P. (2010) Proteomics 10, 30353039.
  • Strand A. D., Aragaki A. K., Shaw D. et al. (2005) Gene expression in Huntington’s disease skeletal muscle: a potential biomarker. Hum. Mol. Genet. 14, 18631876.
  • Tabuchi K., Biederer T., Butz S. and Sudhof T. C. (2002) CASK participates in alternative tripartite complexes in which Mint 1 competes for binding with caskin 1, a novel CASK-binding protein. J. Neurosci. 22, 42644273.
  • Takata K., Kitamura Y., Nakata Y., Matsuoka Y., Tomimoto H., Taniguchi T. and Shimohama S. (2009) Involvement of WAVE accumulation in Abeta/APP pathology-dependent tangle modification in Alzheimer’s disease. Am. J. Pathol. 175, 1724.
  • Trinidad J. C., Specht C. G., Thalhammer A., Schoepfer R. and Burlingame A. L. (2006) Comprehensive identification of phosphorylation sites in postsynaptic density preparations. Mol. Cell Proteomics 5, 914922.
  • Trushina E. and McMurray C. T. (2007) Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 145, 12331248.
  • Videbech P. and Ravnkilde B. (2004) Hippocampal volume and depression: a meta-analysis of MRI studies. Am. J. Psychiatry 161, 19571966.
  • Wellcome Trust Clinical Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661678.
  • Xia H. J. and Yang G. (2005) Inositol 1,4,5-trisphosphate 3-kinases: functions and regulations. Cell Res. 15, 8391.
  • Yang X., Dondeti V., Dezube R., Maynard D. M., Geer L. Y., Epstein J., Chen X., Markey S. P. and Kowalak J. A. (2004) DBParser: web-based software for shotgun proteomic data analyses. J. Proteome Res. 3, 10021008.
  • Yang J. W., Czech T., Felizardo M., Baumgartner C. and Lubec G. (2006) Aberrant expression of cytoskeleton proteins in hippocampus from patients with mesial temporal lobe epilepsy. Amino Acids 30, 477493.
  • Yucel K., McKinnon M. C., Taylor V. H., Macdonald K., Alda M., Young L. T. and MacQueen G. M. (2007) Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study. Psychopharmacology (Berl) 195, 357367.
  • Yucel K., Taylor V. H., McKinnon M. C., Macdonald K., Alda M., Young L. T. and MacQueen G. M. (2008) Bilateral hippocampal volume increase in patients with bipolar disorder and short-term lithium treatment. Neuropsychopharmacology 33, 361367.
  • Zarate C. A., Jr, Singh J. and Manji H. K. (2006) Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol. Psychiatry 59, 10061020.
  • Zhang J., Goodlett D. R. and Montine T. J. (2005) Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases. J. Alzheimers Dis. 8, 377386.